Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients

• Status: Unknown status
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine effect of Fluvoxamine augmentation on cognitive function , aggressive behavior , clinical symptoms and mRNA (messenger ribonucleic acid) and protein expression in human peripheral mononuclear blood cells (PMC) in medicated schizophrenia patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sha'ar Menashe Mental Health Center; Sha’ar Menashe Mental Health Center
• Treatments: Fluvoxamine

Criteria

Inclusion Criteria:

• Age 18-65

• A diagnosis of schizophrenia (DSM-IVTR)

• Antipsychotic dose unchanged for at least 2 weeks prior to study

• SANS score>= 3 on at least one of the global measures of affective blunting, alogia or avolition.

• Knowledge of Hebrew

Exclusion Criteria:

• Dementia or other serious neurological disorders

• History of alcohol or drug use

• Patients with a legal guardian

• Patients involuntarily hospitalized by order of the district psychiatrist

• Use of antidepressants within 1 month of the study

• Renal or hepatic disorder

• Patients with upper GI bleeds

• Patients with SIADH syndrome

• Pregnant woman

Criteria for the cessation of the study after initial commencement

• Severe adverse events (including but not only GI, cardiovascular, neurologic, hematologic or urologic severe adverse events)

• Emergent suicidality

• Emergence of hypomanic or manic symptoms

• If the subject requests to stop